Clearer IP rules in €2 billion pharma project, but biotechs still wary
This article was originally published in Scrip
The €2 billion Innovative Medicines Initiative (IMI), set up by the European Commission and the European pharma trade association EFPIA to kick start consortia research in drug development, has made some progress in pleasing some of its critics, by improving its intellectual property (IP) rules that were seen to mostly benefit big pharma. However, the biotech sector is still finding it a little too complicated.
You may also be interested in...
The US Food and Drug Administration recently signalled its desire to work more closely with other drug regulators in assessing the quality of pharmaceutical manufacturing facilities around the world.
It seems as if the US FDA is softening its stance on assessing the quality of pharmaceutical manufacturing facilities around the world in future, with an apparent desire to work more closely with other drug regulators. However, incorporating the regulators from countries such as India, China and Japan into a global inspectorate still looks problematical.
Large pharmaceutical companies and Médecins sans Frontières may not often see eye-to-eye over access to medicines in poor countries. But it seems as if industry and the humanitarian body, a prominent critic, do agree that competition works in improving access to vaccines, even though they don't agree about the mechanisms of price setting.